Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension

Onal E. M., Sag A. A., Sal O., Yerlikaya A., AFŞAR B., Kanbay M.

CLINICAL AND EXPERIMENTAL HYPERTENSION, cilt.39, sa.3, ss.197-209, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 39 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/10641963.2016.1246565
  • Dergi Adı: CLINICAL AND EXPERIMENTAL HYPERTENSION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.197-209
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Organ crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion.